Researchers Submit Patent Application, "Aldehyde Dehydrogenase Inhibitors and Their Therapeutic Use", for Approval (USPTO 20240174634).

This document discusses the potential therapeutic use of aldehyde dehydrogenase inhibitors (ALDHI compounds) in the treatment of various disorders, including cancer. It highlights the role of ALDH1A3, a specific isoform of the enzyme, in different types of cancer, such as melanoma and breast cancer. Inhibition of ALDH1A3 has been shown to reverse resistance to chemotherapy and enhance the effectiveness of certain drugs. The document also mentions the use of ALDHI compounds in pharmaceutical compositions and provides information on their synthesis and potential therapeutic applications. [Extracted from the article]